Our team has diverse professional experience across the biotech ecosystem, with an established track record in drug development, clinical research, and strategic innovation, ensuring a holistic approach to advancing groundbreaking therapies and transforming patient outcomes.
Guided by social neuroscience, we tackle some of the biggest mental health challenges of our time.
“We work with urgency to support the millions of patients and their loved ones who are suffering from social challenges and substance use disorders.”
– Hugh Alsop, CEO Kinoxis
We are committed to developing novel therapeutics for social challenges and substance abuse disorders.
Hugh Alsop
Chief Executive Officer, Co-Founder
Hugh is an accomplished biotech executive with over 22 years of experience in drug development for global markets pharmaceutical commercialization, international business development…
Michael Bowen
Chief Scientific Officer, Co-Founder
Professor Michael Bowen is one of the lead inventors of the intellectual property licensed by the company and is a leading international expert in translational neuroscience and psychopharmacology…
Sharon Hanegraaf
VP, Drug Development & Strategy
Sharon has over 25 years of experience in international drug development spanning preclinical, clinical, drug development and product registration. Sharon specializes in regulatory strategy and CMC…
Tiina Ahveninen
Director, Clinical Operations
Tiina brings over 25 years of experience in the clinical research industry, including significant leadership roles within global pharmaceutical companies. Her vast operational expertise spans all phases of the clinical trial lifecycle…
Tristan Reekie
Head of Chemistry
Tristan is a co-inventor on the chemistry behind Kinoxis’ development candidates and has over 13 years experience in medicinal chemistry and drug discovery. In addition to being Head of Chemistry…
Cameron Jones
CFO & Company Secretary
Cameron is the managing director of Bio101, a financial services firm providing accounting, taxation and company secretarial services for companies in the life sciences sector. Cameron is a qualified Chartered Accountant…
Dr Peter Devine
Chair
Peter is the CEO of Uniseed, and has extensive experience at board and executive management levels in the commercialisation of early…
Prof. Julie Cairney
Non-Executive Director
Professor Julie Cairney is the Interim Deputy Vice-Chancellor (Research Enterprise) at the University of Sydney, where she…
Dr Kathy Nielsen
Non-Executive Director
Kathy is Director is the CEO of BioCurate and has 25+ years in biomedical/pharma sector and has a strong track record in deal-making…
Dr John Kurek
Non-Executive Director
John brings 20 years of industry experience as a Biotechnology Manager with a focus on the strategic design and implementation…
The Therapeutic Development Team drives the strategic execution of drug development, guiding therapies from preclinical research through clinical trials to commercialization. Working closely with leadership, we advance key programs by integrating scientific innovation and operational excellence to bring novel treatments to patients faster.
The chemistry team at Kinoxis is dedicated to developing innovative treatments for substance use disorders and social dysfunction in mental illnesses. The team consists of skilled and experienced medicinal chemists who use innovative techniques to design novel compounds that feed into Kinoxis’ drug development pipeline.
Our behavioral team utilize the latest in preclinical models, cutting edge neuroscience techniques, and machine learning to discover and develop novel pharmacological treatments for disorders of the brain and mind.
Kinoxis’ pharmacology comprises of highly skilled and collaborative scientists that work closely with our behavioral neuroscience and chemistry team to development novel therapeutics for substance use disorders and social dysfunction in mental illnesses.
Dr Eryn Werry
Tom Wood
© Kinoxis Therapeutics | All Rights Reserved | Website by Graphink Design and Integrale Marketing
